Disability Doc

13.23 Cancers of the female genital tract --carcinoma or sarcoma .

A. Uterus (corpus), as described in 1, 2, or 3:

Corpus – body of the uterus.

1. Invading adjoining organs.

Spread to the pelvic wall equals 13.23 A.1.

OR

2. With metastases to or beyond the regional lymph nodes.

Metastases to regional lymph nodes (or beyond) – will be described in the pathology report (microscopic exam of tissue) or in medical imaging studies, such as MRI or CT scan.

OR

3. Persistent or recurrent following initial antineoplastic therapy.

Persistent – failure to achieve complete remission after completion of initial antineoplastic therapy.

OR

Recurrent – recurrence of the tumor in any part of the body after completion of initial antineoplastic therapy.

OR

B. Uterine cervix, as described in 1 or 2:

Cervix – mouth of the uterus

1. Extending to the pelvic wall, lower portion of the vagina, or adjacent or distant organs.

Will be described in the physical exam, operative report, pathology report (microscopic exam of tissue), or in medical imaging, such as MRI or CT scan.

OR

2. Persistent or recurrent following initial antineoplastic therapy.

Persistent – failure to achieve complete remission after completion of initial antineoplastic therapy.

OR

Recurrent – recurrence of the tumor in any part of the body after completion of initial antineoplastic therapy.

OR

C. Vulva, as described in 1, 2, or 3:

1. Invading adjoining organs.

Spread to the pelvic wall equals 13.23 C.1.

OR

2. With metastases to or beyond the regional lymph nodes.

Metastases to regional lymph nodes (or beyond) – will be described in the pathology report (microscopic exam of tissue) or in medical imaging studies, such as MRI or CT scan.

OR

3. Persistent or recurrent following initial antineoplastic therapy.

Persistent – failure to achieve complete remission after completion of initial antineoplastic therapy.

OR

Recurrent – recurrence of the tumor in any part of the body after completion of initial antineoplastic therapy.

OR

D. Fallopian tubes, as described in 1 or 2:

1. Extending to the serosa or beyond.

Serosa – membrane that lines the organs.

Will be described in the operative report or pathology report (microscopic exam of tissue). Entails extension through the fallopian tube wall to its lining or beyond.

OR

2. Persistent or recurrent following initial antineoplastic therapy.

Persistent – failure to achieve complete remission after completion of initial antineoplastic therapy.

OR

Recurrent – recurrence of the tumor in any part of the body after completion of initial antineoplastic therapy.

OR

E. Ovaries, as described in 1 or 2:

1. All tumors except germ-cell tumors, with at least one of the following:

a. Tumor extension beyond the pelvis; for example, tumor implants on peritoneal, omental, or bowel surfaces.

Peritoneum - membrane that lines the walls of the abdominal cavity

Omentum - folds of the peritoneum that connect the stomach with other abdominal organs 

Will be described in the operative report, pathology report (microscopic exam of tissue), or in medical imaging, such as MRI or CT scan.

OR

b. Metastases to or beyond the regional lymph nodes.

Metastases to regional lymph nodes (or beyond) – will be described in the pathology report (microscopic exam of tissue) or in medical imaging studies, such as MRI or CT scan.

OR

c. Ruptured ovarian capsule, tumor on the serosal surface of the ovary, ascites with malignant cells, or positive peritoneal washings.

Serosa - membrane that lines the organs.

Ascites - fluid in the abdominal cavity.

Peritoneal washings - the intraabdominal cavity is bathed with fluid during the surgical procedure; the fluid is suctioned and sent for examination by a pathologist. If tumor cells are present, the washing is considered "positive."

These findings will be described best in the operative report or pathology report (microscopic exam of tissue).

OR

d. Recurrent following initial antineoplastic therapy.

Recurrent – recurrence of the tumor in any part of the body after completion of initial antineoplastic therapy.

OR

2. Germ-cell tumors--progressive or recurrent following initial antineoplastic therapy.

Germ-cell tumors form in the reproductive cells (egg) of the ovary. Usually occurs in teenage girls and young women. These include dysgerminoma, yolk sac tumors, embryonal carcinoma, immature teratoma, choriocarcinoma, polyembryomas, and mixed germ cell tumors.

In adults, the most majority of germ cell tumors are benign, such as the benign cystic teratoma.

Progressive – malignancy becomes more extensive after completion of initial antineoplastic therapy.

OR

Recurrent – recurrence of the tumor in any part of the body after completion of initial antineoplastic therapy.